Published in N Engl J Med on December 04, 2008
Combined Antihypertensive Therapy and Sexual Dysfunction | NCT01238705
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation (2011) 3.95
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens (2010) 2.12
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens (2015) 2.11
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) (2011) 1.59
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ (2010) 1.58
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res (2012) 1.50
Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res (2014) 1.49
Resistant hypertension: incidence, prevalence, and prognosis. Circulation (2012) 1.46
Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010. PLoS One (2014) 1.45
2010 Canadian Hypertension Education Program recommendations: An annual update. Can Fam Physician (2010) 1.45
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Primary prevention: do the very elderly require a different approach? Trends Cardiovasc Med (2014) 1.43
Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation (2013) 1.41
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension (2012) 1.35
Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep (2010) 1.34
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc (2013) 1.31
Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol (2012) 1.26
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag (2010) 1.17
Initial monotherapy and combination therapy and hypertension control the first year. Hypertension (2012) 1.15
Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med (2012) 1.15
Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc (2010) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens (2014) 1.11
Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Am J Kidney Dis (2011) 1.09
2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol (2014) 1.08
Characterization and treatment of resistant hypertension. Curr Cardiol Rep (2009) 1.07
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens (2011) 1.00
2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol (2010) 0.99
Combination therapy in hypertension: An update. Diabetol Metab Syndr (2010) 0.99
Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (2016) 0.99
Anatomy of success: the top 100 cited scientific reports focused on hypertension research. Hypertension (2013) 0.98
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. PLoS One (2014) 0.96
What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations. Clin Interv Aging (2013) 0.95
Resistant hypertension workup and approach to treatment. Int J Hypertens (2010) 0.94
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens (2010) 0.94
The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics. Pulse (Basel) (2014) 0.92
Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control (2013) 0.92
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T (2011) 0.92
Does it matter how hypertension is controlled? N Engl J Med (2008) 0.91
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag (2009) 0.91
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther (2009) 0.90
INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY). Am Heart J (2013) 0.90
Hypertension in the elderly. World J Cardiol (2012) 0.89
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol (2012) 0.89
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet (2010) 0.89
Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag (2011) 0.89
Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J (2011) 0.88
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol (2012) 0.88
A diet based on multiple functional concepts improves cardiometabolic risk parameters in healthy subjects. Nutr Metab (Lond) (2012) 0.87
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag (2010) 0.87
Adherence to antihypertensive medications: is prescribing the right pill enough? Nephrol Dial Transplant (2014) 0.87
Incremental prognostic value of kidney function decline over coronary artery disease for cardiovascular event prediction after coronary computed tomography. Kidney Int (2015) 0.87
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Timeline of History of Hypertension Treatment. Front Cardiovasc Med (2016) 0.86
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens (2010) 0.86
Management standards for stable coronary artery disease in India. Indian Heart J (2016) 0.86
Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vasc Health Risk Manag (2009) 0.86
Blood pressure lowering in patients with diabetes--one level might not fit all. Nat Rev Cardiol (2010) 0.86
Impact of race on cumulative exposure to antihypertensive medications in dialysis. Am J Hypertens (2012) 0.86
A "patient-tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trial. Med Sci Monit (2013) 0.84
Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care (2011) 0.84
Comparative effectiveness of angiotensin-converting enzyme inhibitors versus beta-blockers as second-line therapy for hypertension. Circ Cardiovasc Qual Outcomes (2010) 0.84
A cross-sectional study of blood pressure control in hypertensive patients in general practice (the I-TARGET study). Cardiovasc J Afr (2009) 0.84
Key advances in antihypertensive treatment. Nat Rev Cardiol (2012) 0.84
Antihypertensive Treatment in the Elderly and Very Elderly: Always "the Lower, the Better?". Int J Hypertens (2011) 0.84
Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control (2013) 0.84
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D (2014) 0.84
Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) (2010) 0.83
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control (2009) 0.83
I brazilian position paper on antihypertensive drug combination. Arq Bras Cardiol (2014) 0.83
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc Health Risk Manag (2009) 0.83
New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension (2010) 0.83
Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. J Hypertens (2014) 0.83
Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens (2011) 0.83
The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: Its Essentials and Key Points. Pulse (Basel) (2015) 0.82
Renal denervation with standard radiofrequency ablation catheter is effective in 24-hour ambulatory blood pressure reduction - follow-up at 1/3/6/12 months. Neth Heart J (2016) 0.82
Telemonitoring and Protocolized Case Management for Hypertensive Community-Dwelling Seniors With Diabetes: Protocol of the TECHNOMED Randomized Controlled Trial. JMIR Res Protoc (2016) 0.82
Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res (2014) 0.82
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 3.89
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol (2013) 3.15
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (2003) 3.09
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Retracted Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J (2009) 2.83
Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension (2006) 2.83
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem (2011) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol (2008) 2.63
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol (2011) 2.40
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol (2010) 2.39
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J (2011) 2.33
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol (2010) 2.29
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol (2009) 2.19
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet (2003) 2.17
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med (2008) 2.11
Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10